Fig. 7: Investigating the potential of ANBL-6 for preclinical in vivo modeling in myeloma. | Leukemia

Fig. 7: Investigating the potential of ANBL-6 for preclinical in vivo modeling in myeloma.

From: Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis

Fig. 7: Investigating the potential of ANBL-6 for preclinical in vivo modeling in myeloma.

a 1e6 luciferase-labeled ANBL-6 and MM.1S cells were implanted via tail vein injection into NSG on the same date. Bioluminescence imaging (BLI) data are shown at noted dates post implant. Both cell lines show identical localization, primarily to long bones of hindlimbs and to the spine. Note scale bar with lower intensities for BLI signal in ANBL-6. b Quantification of BLI signal (n = 4 in ANBL-6 arm; n = 6 in MM.1S arm). c Survival of MM.1S-implanted mice versus ANBL-6 implanted mice illustrates more indolent course of ANBL-6 in vivo. p value by log-rank test.

Back to article page